Genome Editing for the treatment of human Disease Network

GenEHumDi recommended activities

Events in November 2025

MMonday	TTuesday	WWednesday	TThursday	FFriday	SSaturday	SSunday
27October 27, 2025	28October 28, 2025●●(2 events) Close 2025 ARRIGE Annual Meeting :Access and Affordability of Gene Therapies - Challenges for Genome Editing October 28, 2025 – October 29, 2025 Join us at ARRIGE annual meeting for a two half-day meeting exploring the pressing ethical, social, and policy issues surrounding access to and affordability of emerging gene therapies developed through genome editing technologies. The event will bring together researchers, clinicians, policy makers, regulators, biotech entrepreneurs, pharma and patient advocates to discuss equity, innovation, and global health implications. Read more 2025 ARRIGE Annual MeetingOctober 28 & 29, 2025 October 28, 2025 – October 29, 2025 Read more	29October 29, 2025●●(2 events) Close 2025 ARRIGE Annual Meeting :Access and Affordability of Gene Therapies - Challenges for Genome Editing October 28, 2025 – October 29, 2025 Join us at ARRIGE annual meeting for a two half-day meeting exploring the pressing ethical, social, and policy issues surrounding access to and affordability of emerging gene therapies developed through genome editing technologies. The event will bring together researchers, clinicians, policy makers, regulators, biotech entrepreneurs, pharma and patient advocates to discuss equity, innovation, and global health implications. Read more 2025 ARRIGE Annual MeetingOctober 28 & 29, 2025 October 28, 2025 – October 29, 2025 Read more	30October 30, 2025	31October 31, 2025	1November 1, 2025	2November 2, 2025●(1 event) Close EMBO CourseCRISPR-CasFrom biology to therapeutic applications 12:00 am – 1:00 am November 2, 2025 – November 5, 2025 Read more
3November 3, 2025●(1 event) Close EMBO CourseCRISPR-CasFrom biology to therapeutic applications 12:00 am – 1:00 am November 2, 2025 – November 5, 2025 Read more	4November 4, 2025●(1 event) Close EMBO CourseCRISPR-CasFrom biology to therapeutic applications 12:00 am – 1:00 am November 2, 2025 – November 5, 2025 Read more	5November 5, 2025●(1 event) Close EMBO CourseCRISPR-CasFrom biology to therapeutic applications 12:00 am – 1:00 am November 2, 2025 – November 5, 2025 Read more	6November 6, 2025	7November 7, 2025	8November 8, 2025	9November 9, 2025
10November 10, 2025	11November 11, 2025	12November 12, 2025	13November 13, 2025	14November 14, 2025	15November 15, 2025	16November 16, 2025
17November 17, 2025	18November 18, 2025	19November 19, 2025	20November 20, 2025	21November 21, 2025	22November 22, 2025	23November 23, 2025
24November 24, 2025	25November 25, 2025	26November 26, 2025	27November 27, 2025	28November 28, 2025	29November 29, 2025	30November 30, 2025

Last GenEHumDi Blog entry

WG3 & WG5 joint meeting – Ankara 25.9.2025

Mapping and Evaluating Delivery Methods for GeneEditing in Clinical Applications GeneHumdi COST Action's Working Group 3 (Delivery) and Working Group ...

Read More

Welcome to the Genome Editing for the treatment of human Disease Network (GeneHumdi | COST action CA21113) Website. We are Academia and industry scientist, translational scientist, clinicians, regulatory agents, and industry partners dedicated to the improvement and translation of Gene Editing protocols to treat diseases lacking sound medical care or susceptible of increase safety and control of the therapeutic interventions through the implementation of precision gene medicine.

Recent advances on genome editing (GE) technologies have opened the possibility of treating diseases through precise modifications of patients’ genomes. Impressive results have been achieved on animal models of several genetic disorders, infectious diseases as well as cancer and several clinical trials are already on going. However, the inadequate integration of the results of academic research into the research development strategy of pharmaceutical companies, the insufficient interest of academic institution in regulatory science and the absence of established standards to well acceptable risk-benefit ratio by regulatory agencies, preclude its general application for treating human diseases. Therefore, the translation of the GE technologies to address public health needs, require a strong collaboration between basic and clinical research, regulatory bodies and the different stake holders involved for each application. There are several networks to improve or analyse GE technologies for different applications, however, no one cover all the actors involved in gene therapy translation.

The principal aim of the GeneHumdi Action is to bring together pharmaceutical companies, academic institution, science and regulatory agencies, biotechnology firms, patient advocacy association and information technology, in order to tackle knowledge fragmentation with the aim to accelerate the translation of GE technologies to the treatment of human diseases. GeneHumdi is supported by COST (European Cooperation in Science and Technology) which is a funding organisation for research and innovation networks operating in Europe since 1971. In their organigram, GeneHumdi nourishes from the ideas exchange of Management Committee (MC) members from over 24 EU Countries and MC and other members are organized into Working Groups (WG) to distribute GeneHumdi workload and allocate specific question to dedicated experts in each field.